ALZAMEND NEURO, INC. Accounts Payable and Accrued Liabilities, Current
ALZAMEND NEURO, INC. (ALZN) had Accounts Payable and Accrued Liabilities, Current of $2.74 million as of 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent · last filed 2026-09-10
- 2026-07-31: Accounts Payable and Accrued Liabilities, Current $2.74M.
- 2026-04-30: Accounts Payable and Accrued Liabilities, Current $1.35M.
- 2026-01-31: Accounts Payable and Accrued Liabilities, Current $1.86M.
- 2025-10-31: Accounts Payable and Accrued Liabilities, Current $717.49K.
| Period end | Accounts Payable and Accrued Liabilities, Current |
|---|---|
| 2026-07-31 | $2.74M 10-Q · filed 2026-09-10 |
| 2026-04-30 | $1.35M 10-Q · filed 2026-09-10 |
| 2026-01-31 | $1.86M 10-Q · filed 2026-03-11 |
| 2025-10-31 | $717.49K 10-Q · filed 2025-12-09 |
| 2025-07-31 | $983.31K 10-Q · filed 2025-09-10 |
| 2025-04-30 | $634.76K 10-K · filed 2026-07-22 |
| 2024-04-30 | $2.93M 10-K · filed 2025-07-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |